Breaking Down the £1.6 Billion Takeover of Assura by KKR and Stonepeak
In a move that’s set to reshape the UK’s healthcare property landscape, private equity giants KKR and Stonepeak have tabled a recommended cash offer to acquire FTSE 250 real estate investment trust (REIT) Assura plc. Let’s unpack what this means for shareholders, the sector, and the future of critical healthcare infrastructure.
The Deal at a Glance
Here’s the headline stuff:
- Offer Price: 49.4 pence per share – a blend of 48.56p cash and a 0.84p final dividend.
- Premium: 31.9% above Assura’s pre-offer share price (37.4p on 13 February 2025).
- Total Valuation: £1.6 billion, matching Assura’s EPRA Net Tangible Assets (NTA) – a key real estate valuation metric.
- Structure: Scheme of arrangement requiring 75% shareholder approval.
Why Healthcare Real Estate? Why Now?
This isn’t just another property play. Assura’s portfolio of 600+ NHS GP surgeries, hospitals, and specialist care facilities represents essential infrastructure with inflation-linked rents. For KKR and Stonepeak, it’s a classic infrastructure investment:
- Predictable long-term cash flows
- Exposure to ageing populations and healthcare demand
- Opportunity to accelerate development without public market pressures
“Private ownership allows sustained capital investment without asset sales,” notes KKR’s Tara Davies – a clear dig at REITs’ traditional ‘recycle capital’ model.
The Strategic Playbook
Both buyers are deploying their core infrastructure strategies – KKR’s open-ended fund and Stonepeak’s Global Core vehicle. Their game plan?
- Leverage operational expertise from deals like Northumbrian Water (KKR) and euNetworks (Stonepeak)
- Tap into £20bn+ of combined UK infrastructure experience
- Support Assura’s B Corp status and sustainability goals (a first for FTSE 250)
Shareholder Calculus: To Accept or Not?
With the board’s backing and a 100% EPRA NTA price, the case for accepting seems strong. But let’s crunch the premiums:
| Benchmark | Premium |
|---|---|
| 1-month VWAP | 33.9% |
| 3-month VWAP | 30.6% |
Yet the real juice? KKR had to up its offer five times – from an initial 48p – seeing off rival interest from Primary Health Properties.
Roadmap to Completion
Mark your calendars:
- Scheme Document: Due by 7 May 2025
- Court Meeting: Expected late Q2 2025
- Effective Date: Target early Q3 2025
Regulatory clearances in China, EU, Israel, South Korea, and Ireland remain key hurdles – though no major antitrust issues are anticipated.
The Bottom Line
This deal crystallises value for shareholders while giving Assura the firepower to modernise UK healthcare estates. As Stonepeak’s Nikolaus Woloszczuk puts it: “It’s about ensuring these assets fulfil their essential role sustainably.”
For investors? 49.4p offers a clean exit amid volatile REIT valuations. For the NHS? Potentially faster delivery of the facilities GPs desperately need. Watch this (hospital) space.
